You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Chemistry
- Asymmetric Synthesis
- High-Speed Synthesis and purification
- Metabolite Synthesis (Phase I and II)
- Molecular Probes (Fluorophores and Biotinylated Targets)
- Structure Identification and Characterization
- Stable Isotopically Labeled Compounds (2H, 13C, 15N, 34S)
- Specific Chemistry Expertise
- Natural Product Synthesis
- Instrumentation and Computing
Metabolite Synthesis (Phase I and II)
During phase I metabolism a chemically reactive or pharmacologically active molecule can develop or a nontoxic compound can turn into a poisonous metabolite. During phase II metabolite conjunction may result in the formation of specific chemical structures that are linked to potential toxicity. Phase I or II metabolites can be optimized and produced directly from drug candidates for use in safety assessment studies.
- Glucuronide synthesis
- Sulfates
Learn more about